

**Allium Expands its Activities to South America  
Signed an exclusive distribution agreement in  
Argentina at an overall amount of at least NIS 2.7  
million over five years**

**The distributor, which is currently in advanced regulatory processes,  
will bear all registration and marketing costs**

**Sales initiation is expected in the upcoming year**

**Since the beginning of the year, Allium signed distribution agreements  
in Russia, the Czech Republic, Slovakia, India, Canada, Kazakhstan,  
Taiwan and Turkey**

Caesarea, Israel - September 2, 2015: Allium Medical Solutions Ltd (TASE: ALMD), a company that specializes in minimally invasive technologies, announced today that it has signed an exclusive distribution agreement for Allium's urological stents in Argentina. The distributor partner is a seasoned and experienced company that has been operating in the Argentinian market since 1978, and specializes in the import and distribution of products in the field of urology. The company is deeply familiar with the market and its needs, and operates in both the public and private sector across Argentina - both directly and through sub-distributors. The Argentinean distributor distributes products of leading medical device companies.

**Asaf Alperovitz, CEO of the Allium Group:** "We are very excited to sign a second exclusive distribution agreement during this past week, and this time targeting the Latin America market. This agreement is significant for Allium, both from potential revenue and profitability, and on the level of penetration to attractive and developing active markets. This agreement is added to those we have recently signed in Russia, the Czech Republic, Slovakia, India, Canada, Kazakhstan, Taiwan and Turkey as part of our business strategy for creating new growth engines

for the company. This agreement, in addition to countries where we are undergoing regulatory processes, such as China and South Korea, enable us to expand the base of our commercial activities beyond European markets in which we are focused today. Entering new territories was meant to establish a strong infrastructure for developing markets adopting innovative minimally invasive technologies, which we believe will already allow us to present significant growth in sales in 2016.

"The agreement that was signed is the fruit of a thorough and professional process, in which we assessed the market together with the distributor for the potential it holds for the company's products. We believe the agreement reconfirms the innovation and unique advantages contained in the company's products. Over the long term, this cooperation could be the anchor for expanding the commercial activity in other central markets in South America. It is our intention to promote additional distribution agreements, based on the regulatory approvals and the company's innovative products, with the goal of creating value for our shareholders", summarized Alperovitz.

The agreement is exclusive and valid for a period of five years, beginning when the regulatory approvals are obtained for sales in Argentina, a process which is currently in its advanced stages. As part of the agreement, the distribution company has committed to purchase Allium's urological stents at an overall amount of at least NIS 2.7 million over a period of five years, and according to minimum annual purchase requirements that have been set. The company believes the distributor will commence sales under this agreement during the upcoming year, subject to obtaining the required regulatory approvals. Within the framework of the agreement, the distributor has fully undertaken the duty of obtaining the regulatory approvals required for sales in Argentina and to bear all the registration costs, to take marketing steps according to an annual plan that was coordinated with the company, and to hold instructional workshops for doctors that will be using the company's products. The agreements include provisions concerning the protection of the company's intellectual property rights, confidentiality, indemnification, the parties' limits of liability, and additional provisions that are practically acceptable in medical devices distribution agreements. In the event the distributor will meet all of its contractual obligations, the agreement will be extended for an additional periods.

### **About Allium Medical**

Allium is an Israeli company that specializes in minimally invasive medical solutions and presents a variety of technologies and product lines in this area. The Company's strategy is to create value by expanding the basis of internal developments and by purchasing product lines and additional technologies. The Company is run by leading professionals with knowhow and experience in rapid promotion of products, from the development stage to the commercial stage, while ensuring long-term financing and economies of scale.